First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
We have improved our eMediNexus Platform with a far superior user experience.
Please click here to try it
Editor-in-Chief eMediNexus – Dr KK Aggarwal
25th July 2018
Capping in health insurance benefits the patient in the long run

Dr KK Aggarwal, Recipient of Padma Shri

The rising health care costs are taking a toll on people, especially the poor as well as the middle class. This is because of the very high out-of-pocket expenditure on health care due to the dismal spending on health by the government. Having a health insurance plan is gradually becoming inevitable.

One can have two types of health insurance with limited coverage or unlimited coverage. For example, we may take an insurance of five lakhs for the full year with a small premium of Rs 500/- per month. We may not be able to afford a coverage of one crore. more

Top News

WHO calls for urgent action to accelerate HIV response in Eastern Europe and central Asia

Ministers of health and senior policy-makers from 10 countries in Eastern Europe and central Asia (EECA) gathered for a ministerial policy dialogue on HIV and related comorbidities to revamp political commitment to fight HIV and scale up the HIV response. The policy dialogue, organized by WHO in cooperation with the Government of the Netherlands and the Joint United Nations Programme on HIV/AIDS (UNAIDS), took place on 23 July 2018 in Amsterdam, the ... read more

Morning Medtalks

Morning MEDTalks with Dr KK Aggarwal 25th July 2018

Letter to editor about NEET age Respected Dr KK Aggarwal Sir We a group of students above the age of 25 are in dilemma. We had given NEET-UG on 6th of May this year. On 4th of June, CBSE declared the result but did not declare result of students of above age 25. Now the registration for counselling have been started. We want to become doctors. No one has the right to spoil our life. Why is there a barrier of maximum age limit for becoming Doctor in India? This is the main reason for students to go to other countries for becoming a doctor and settle there forever. At present, there is already shortage of doctors in our country. .. read more

Practice Updates

Eating orange daily reduces risk of ARMD

Eat an orange every day reduces risk of age-related macular degeneration (ARMD), suggests a study published July 6 in the American Journal of Clinical Nutrition. In the study, people who ... read more

Omega-3 fatty acids do not improve heart health, finds Cochrane review

A Cochrane systematic review of 79 studies involving more than 112,000 people found no evidence that increasing consumption of alpha ¬linolenic acid (ALA) and the long-chain omega-3 fatty acids (LCn3) eicosapentaenoic acid or docosahexaenoic acid enhances cardiovascular ... read more

No increased risk of major adverse cardiac events found with lorcaserin

Results from a 12,000 patient post-marketing safety study mandated by the US Food and Drug Administration (FDA) show that lorcaserin, the obesity drug does not increase the risk of any major adverse cardiac events (MACE), which included cardiovascular death, nonfatal myocardial ... read more

New fathers screen positive for depression as often as new mothers

A study published online July 23, 2018 in JAMA Pediatrics suggests routine screening of both parents during well-child care visits as paternal depression is also as likely to occur as postpartum depression in new mothers.... read more

ABILITY-3 shows higher rates of maintenance remission with adalimumab

In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued treatment with adalimumab was associated with significantly fewer patients flaring compared with treatment withdrawal. These findings from the ABILITY-3 trial were ... read more

eMedi Humor
Medicolegal Corner
eMedi Quiz
a. Neutrophil
b. Macrophage
c. Histiocyte
d. Dendritic cell
Lifestyle Updates
Inspirational Story 1: If and When
Inspirational Story 2: The Three Races
Malaria may become treatable with the approval of tafenoquine
Treatment is the second step; the first is prevention from the disease and stopping transmission
New Delhi, 24th July 2018: The USFDA has given its approval for a new drug called Krintafel (tafenoquine) to treat P. vivax malaria relapse, which accounts for 34% of the estimated 13 million cases in India.

The drug has been developed by a not-for-profit research and industry partnership and is the first new treatment for the disease in more than 60 years. It is most likely to get fast-tracked approvals for use globally. It is a single-dose, ‘radical cure’ treatment (when given with chloroquine) for ages 16 years and older that kills dormant infection in the liver to prevent relapse.

To Read More or Comment, Click Here